CRAM
PFE icon

Compass Rose Asset Management’s Pfizer PFE Stock Holding History

Compass Rose Asset Management’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,035,000
Closed -$29.8M – 10
2023
Q4 		$29.8M Buy
+1,035,000
New +$31.3M 12.46% 2

Other funds holding PFE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Compass Rose Asset Management's PFE Position: Q1 2024 in Review

Compass Rose Asset Management sold out of Pfizer (PFE) in Q1 2024, closing a stake of 1,035,000 shares — an estimated $29.8M sold.

Compass Rose Asset Management first reported a position in PFE in Q4 2023 and held it in 1 quarter. The position peaked at $29.8M in Q4 2023. 2,874 funds tracked by Wall St. Rank hold PFE as of Q1 2024.

  • Compass Rose Asset Management reported no remaining Pfizer position as of Q1 2024 after selling out during the quarter.
  • Compass Rose Asset Management sold 1,035,000 Pfizer shares in Q1 2024, an estimated $29.8M.
  • Compass Rose Asset Management first reported a position in Pfizer in Q4 2023 and held it in 1 quarter.
  • Compass Rose Asset Management's Pfizer position peaked at $29.8M in Q4 2023.
  • 2,874 funds tracked by Wall St. Rank held Pfizer as of Q1 2024.

Based on Compass Rose Asset Management's 13F filing for Q1 2024, filed 15 May 2024.